BCL2 and non-small cell lung carcinoma: In our current study, we found that the BCL2-938 A variant was associated with poor PFS and OS of patients with advanced NSCLC after chemotherapy, which supports previous data reported by Katsuhiro Masago and colleagues of 168 advanced NSCLC patients who received platinum-based chemotherapy20.